Serum antibody coupled with the construction of gentamicin sulfate for the Escherichia coli targeted drug

Research in Veterinary Science

Volumn 91, Issue 3, 2011, Pages

  Dong, Wei ^a   Chen, Xiaojun ^a   Liu, Ke ^a   Chen, Haitao ^a   Sun, Zhiliang ^a  

^a HUNAN AGRICULTURAL UNIVERSITY   (China)

Author keywords

Antibody; Conjugate; E. coli; Gentamicin sulfate

Indexed keywords

GENTAMICIN; GENTAMICIN SULFATE ANTIBODY CONJUGATE; MACROGOL 6000; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RABBIT;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENTAMICINS; MICE; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 80555135438     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2011.01.016     Document Type: Article

References (36)

1. Athamna A., Athamna M., Medlej B., Bast D.J., Rubinstein E. In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis. J. Antimicrob. Chemother. 2004, 53:609-615.
2. Arthur L., William C., Harriette N., Barth R., Christine S., Jana S. Methods for determining bactericidal activity of antimicrobial agents: approved guideline. NCCLS 1999, 19:23-29.
3. Ball P., Baquero F.O., Cars T., File J.Garau, Klugmanf K., Lowg D.E., Rubinsteinh E., Wisei R. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. Antimicrob. Chemother. 2002, 49:31-40.
4. Boswell F.J., Andreews J.M., Wise R. Bactericidal properties of moxifloxacm-1 and post antibiotic effect. J. Antinderobchemother. 1999, 43:206-211.
5. Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert. Opin. Biol. Ther. 2005, 5:1085-1093.
6. Cary D.A., Wen Xiaohui, Lewis G., Christopher N., Richard H.S., Suzie J.Scales Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. PNAS 2005, 102:17987-17992.
7. Charlotte F., McDonagh Eileen T., Lori W., Jennifer W.B., Stephen C.A., Kristine K., Jamie A., Ivan S., Kevin J.H., Joseph A.F., Paul C. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein. Eng. 2006, 19:299-307.
8. Che-Leung L., Kristine A.G., Brian E.T., Andrew K.Y., Michelle A.H., Charles G.C., Joseph M.P., Maureen C.R., Leia S., Ronald S., Guido S., Ezogelin O., Svetlana O.D., Damon L.M., Joseph A.F., Paul C., Peter D.S., John A.C., Christopher G.W., Alan F.W. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 2006, 66:2328-2337.
9. Craig W.A. The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. Respir. Med. 2001, 95:512-519.
10. Duncan R., Vicent M.J., Greco F., Nicholson R.I. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr. Relat. Cancer 2005, 12:S189-S199.
11. Forssen E.A., Ross M.E. Daunoxome treatment of solid tumers: preclinical and clinical investigations. J. Liposome. Res. 1994, 4:481-512.
12. Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspension. Nat. Phys. Sci. 1973, 241:20-22.
13. Gary L.G., Jules M., Rhona S., Serengulam V.G., Ivan D.H., H J.H., David M.G. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin. Cancer Res. 2003, 9:6567.
14. Gooris Bouwstra Infrared spectroscopic study of stratum corneum model membranes prepared from human ceramides, cholesterol, and fatty acids. Biophys. J. 2007, 92:2785-2795.
15. Hall R.M., Brookes D.E., Stokes H.W. Site-specific insertion of genes into integrons: role of the 59-base element and determination of the recombination cross-over point. Mol. Microbiol. 1991, 5:1941-1953.
16. Iftach Y., Marina S., Hagit B., Doron S., Itai B. Targeting antibacterial agents by using drug-carrying filamentous bacteriophages. Antimicrob. Agents Chemother. 2006, 50:2087-2097.
17. Ismail M., El-Kattan Y.A. Comparative pharmacokinetics of marbofloxacin in healthy and Mannheimia haemolytica infected calves. Res. Vet. Sci. 2007, 82:398-404.
18. Jun Y., Chen Hongtao, Iontcho R.V., Cheng Ji-Xin, Philip S.Low Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J. Pharmacol. Exp. Ther. 2007, 321:462-468.
19. Kevin H., Peter S., Dana C., Michael M.C.S., Joel L., Charles C., Kim K., Starr B., Anastasia K., Roger Z., Damon M., Joseph Francisco Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 2004, 10:7063-7070.
20. Martin T., Lars B. Unconventional natural sources for future drug discovery. Drug. Discovery. Today. 2004, 9:450-458.
21. Merrill D.B., Ahmari S.E., Bradford J.M., Jeffrey A.L. Myocarditis during clozapine treatment. Am. J. Psychiatry. 2006, 163:204-208.
22. Michael E.K., Erika J.E., Russell E.L., Michael E.E., Michael A.P. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents CH 1998, 42:1207-1212.
23. Moats R.K., Ramirez V.D. Electron microscopic visualization of membrane-mediated uptake and translocation of estrogen-BSA:colloidal gold by Hep G2 cells. J. Endocrinol. 2000, 166:631-647.
24. Moe H.K., Ruth L., William S., Allen S.Craig, James H., Arthur R., Ann R.T., Lee H.H., Nancy M.B., Monica M.F., Richard R.F., James H.J., John B., Elizabeth R.Z., Anne Schuchat, Cynthia G. Effect of Introduction of the pneumococcal conjugate vaccine on drug-resistant streptococcus pneumoniae. N. Engl. J. Med. 2006, 354:1455-1463.
25. Ong C.T., Dandekar P.K., Sutherland C., Nicolau D.P. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy 2005, 51:339-346.
26. Pao W., Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell-lung cancer: current knowledge and future directions. J. Clin. Oncol. 2005, 23:2556-2568.
27. Raizer Jeffrey HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiform. J. Neurooncol. 2005, 74:77-86.
28. Ricci M., Blasi P., Giovagnoli S., Rossi C. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue. Med. Chem. 2006, 13:1757-1775.
29. Schentag J.J., Klugman K.P., Yu V.L., Adelman M.H., Gregory J., Christine C., Manish P., Bruce L., Joseph P. A Streptococcus pneumoniae bacteremia: pharmacodynamic correlations with outcome and macrolide resistance a controlled study. Int. J. Antimicrob. 2007, 30:264-269.
30. Sheila K.S., Saralee B., Michael R.J., Peter C.A. Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria. Antimicrob. Agents. CH 2000, 44:186-189.
31. Shen B., Nonaka K. Enediyne natural product: biosynthesis and prospect towards engineering novel antitumor agents. Bentham Science Publishers 2005, 2:357-369.
32. Simmons T., Kerry L., McPhail, Eduardo O.B., Susan L., William H. Belamide A, a new antimitotic tetrapeptide from a Panamanian marine cyano-bacterium. Tetrahedron. Lett. 2006, 247:3387-3390.
33. Todd P., Ruthven N., Ronald N. Differential scanning calorimetric and Fourier transform infrared spectroscopic studies of the effects of cholesterol on the thermotropic phase behavior and organization of a homologous series of linear saturated phosphatidylserine bilayer membranes. Biophys. J. 2000, 79:2056-2065.
34. Wilson G.D., Bentzen S.M., Harari P.M. Biologic basis for combining drugs with radiation. Semin. Radiat. Oncol. 2006, 16:2-9.
35. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992, 1113:171-199.
36. Yelena Kovtun, Charlene Audette, Yumei Y., Hongsheng X., Mary Ruberti, Sara J.P., Barbara A.Leece, Thomas C., Walter B., Victor S. Goldmacher antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006, 66:3214-3221.